Newcure

NewCure is a biotechnology company focused on developing small molecule inhibitors targeting Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome tautomerase (D-DT). Founded by researchers from Yale University, the company leverages deep expertise in the MIF pathway to address critical unmet needs in oncology and immunology. Their lead programs aim to modulate the immune microenvironment to overcome tumor-induced immunosuppression and treat chronic inflammatory conditions. By inhibiting these pro-inflammatory cytokines, NewCure seeks to provide novel therapeutic options for patients with solid tumors and autoimmune disorders such as lupus and multiple sclerosis.